<SEC-DOCUMENT>0001193125-24-218503.txt : 20240913
<SEC-HEADER>0001193125-24-218503.hdr.sgml : 20240913
<ACCEPTANCE-DATETIME>20240913091409
ACCESSION NUMBER:		0001193125-24-218503
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20240913
DATE AS OF CHANGE:		20240913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-280447
		FILM NUMBER:		241296580

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d881869d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-280447</FONT> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
June&nbsp;24, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>1,100,000 American Depositary Shares representing 11,000,000 Ordinary Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g881869g0913171743297.jpg" ALT="LOGO" STYLE="width:2.22014in;height:0.625694in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated June&nbsp;24, 2024 (the
&#147;Prospectus&#148;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-280447),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on September&nbsp;13, 2024 (the &#147;September 13, 2024 Form <FONT STYLE="white-space:nowrap">6-K&#148;).</FONT> Accordingly, we have
attached the September&nbsp;13, 2024 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates
and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be
read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#147;Nasdaq&#148;) under the symbol &#147;KZIA.&#148; On September&nbsp;12, 2024, the last reported sale
price of the ADSs on Nasdaq was $0.3465 per ADS. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities
involves a high degree of risk. See &#147;Risk Factors&#148; beginning on page 9 of the Prospectus and the &#147;Risk Factors&#148; in &#147;Item 3. Key Information&#151;D. Risk Factors&#148; of our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">20-F,</FONT> which is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of
this prospectus supplement is September&nbsp;13, 2024 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of September, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;</FONT> Form <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&nbsp;12, 2024, Kazia Therapeutics Limited (the &#147;Company&#148;) issued a press release titled, &#147;Kazia Executes
Licensing Agreement with QIMR Berghofer&#148;. A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the respective quotes of
Dr.&nbsp;John Friend, Chief Executive Officer of the Company, and Professor Fabienne Mackay, Director and Chief Executive Officer of QIMR Berghofer, contained in Exhibit 99.1, into the Company&#146;s registration statements on Form <FONT
STYLE="white-space:nowrap">F-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-276091</FONT> and <FONT STYLE="white-space:nowrap">333-281937).</FONT></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated September&nbsp;12, 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited </B>(Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John Friend</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 13&nbsp;September 2024</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g840862dsp4.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>12&nbsp;September 2024 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KAZIA EXECUTES LICENSING AGREEMENT WITH QIMR BERGHOFER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, September&nbsp;12, 2024 &#150; Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce that an
agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia&#146;s foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies
consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the license agreement, Kazia receives
an exclusive, worldwide, <FONT STYLE="white-space:nowrap">sub-licensable</FONT> and royalty-bearing licence to certain intellectual property for the development of any drugs or product candidates within the PI3K inhibitor class in combination with
immunotherapy or PARP inhibitors. Paxalisib, Kazia&#146;s lead product candidate, is a member of the PI3K inhibitor class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exclusive license
agreement follows a collaboration between Kazia and QIMR Berghofer which began in December 2022 and has already led to the filing of supportive patents which include the use of paxalisib as an immune modulator in the treatment of diseases such as
breast cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of the license include standard provisions for an upfront license fee and development milestones related to the initiation of
Phase 1, Phase 2 trial, first Phase 3 trial, first product approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenting on the new license agreement, Kazia CEO, Dr John Friend said: &#147;This
is an exciting evolution in our partnership with QIMR Berghofer and an important milestone for not only Kazia&#146;s development of paxalisib, but also the company&#146;s commercial portfolio as we secure the licence of a significant cancer
immunotherapy pathway. We are very pleased to have obtained the potential intellectual property rights around PI3K inhibitors, which is a significant step forward as we continue to explore cancer treatments beyond the brain, including novel
therapeutics in solid tumours such as breast cancer.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professor Fabienne Mackay, Director and CEO of QIMR Berghofer said: &#147;We are pleased to
enter this exclusive licence agreement with Kazia following what has been a successful research collaboration over the past two years. We look forward to progressing the clinical development pathway for PI3K inhibitor drugs such as paxalisib under
this partnership in the hope of delivering tangible, life-changing benefits to patients.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia&#146;s preclinical research collaboration with QIMR
Berghofer Medical Research Institute is investigating the use of paxalisib in solid tumours. The ongoing research project is led by Professor Sudha Rao, a leading expert in transcriptional biology, particularly as it applies to the function of the
immune system in cancer. Prof Rao is the principal investigator of preclinical studies where paxalisib and KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> combination is used in Triple Negative Breast Cancer, and paxalisib and
LYNPARZA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (Olaparib) combination in advanced breast cancer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g840862dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Professor Rao&#146;s team has demonstrated in preclinical studies that the combination of paxalisib with
checkpoint inhibitor blockade resulted in highly consistent and statistically significant signals of efficacy including overall tumour volume, metastases, and inflammatory markers. Furthermore, the addition of paxalisib to immunotherapy was observed
to reinvigorate the immune cells within the tumour microenvironment by restoring immune killing function while inhibiting <FONT STYLE="white-space:nowrap">&#147;pro-tumour&#148;</FONT> immune cells. Further data is expected to be presented at future
scientific meetings in 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Commenting on the research, Prof Rao said: &#147;The immune system plays a critical role in fighting against cancer. We
urgently need treatments that can make cancer cells visible, and at the same time increase the utility of immunotherapy for metastatic breast cancers. In that sense, paxalisib is an exciting PI3K inhibitor because it not only has been observed to
inhibit primary tumour burden but was also observed to reinvigorate the immune system of cancer patients. We look forward to providing a preliminary update in the near future on our findings of using paxalisib in breast cancer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">About Kazia Therapeutics Limited </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited
(NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, an investigational
brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A
completed Phase 2 study in glioblastoma reported early signals of clinical activity in 2021, and a pivotal study in glioblastoma, GBM AGILE, has been completed with presentation of paxalisib arm data expected later in 2024 at a major medical
conference. Other clinical trials involving paxalisib are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these trials having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the FDA in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in
August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumour brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation
and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumours in June 2022 and July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and presentation of preliminary data at a medical conference is anticipated in CY2024. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g840862dsp4.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Forward-Looking Statements </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain
forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148; &#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any
statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements
regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials and investigator-initiated trials of Kazia&#146;s product candidates, the potential benefits of Kazia&#146;s product candidates, including paxalisib,
and Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801. Such statements are based on Kazia&#146;s current expectations and projections about future events and future trends affecting its business and are
subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product
development, related to regulatory approvals, risks related to collaborations with third parties, and related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual
Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the United States Securities and Exchange Commission (SEC), and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward- looking
statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for release by Dr John Friend, CEO. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>END </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g840862dsp4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g840862dsp4.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M5:FN&Q*K4N>6EMR];7EO>1F2VF250<$J<XK&4)0=I*QT0J0J*\'<FS4EAF@
MS0 9H ,T &: #- !F@ S0 9H ,T &: #- !F@ S0 9H ,T &: #- !F@ S0
M4 +0 AH R+[Q)8:?>_99?,+C&XJN0OUKIIX:=2/,CBJXVE1GR2,?4/#%U?:L
MUU#/&;>9@^XGE1].]=-/%1A3Y6M4<5; 3JU>>+T9T-YH]C?M&]U )'08#9()
M'OCK7%"M.GI%GI5,-2JM.:O8B<:/JRMI_F03>1UC1QE,<=NE13KN,FXO4WK8
M*]->TA[O09J&B1RZ(^GV06 9#*.Q(/>MJ==JISSU.2MA5*@Z5/0S-+M3X7L[
MB[U&0?O"JJD?.>OZUO5G]9DHTSDP]/ZC"4ZKW[&WI>K6VK0-);[AL.&5A@BN
M6K1E2=I'?0Q$*\;P+U9'0% ' ZE\5M*TS7+C2Y;"[9X)O)9UVXSG&1S6BIMJ
MYFZB3L=O>7EOI]E-=W4JQ6\*EW=N@ K-*YIL<3I'Q5TW6M:M],L],OFDG?:K
M87 ']XC/  YK1TVE<S51-V1WM9F@4 8_B;Q%:^%]$DU*Z1I K!$C4X+L>P_4
M_A51CS.PI/E5R_I]]!J>G6]];-N@N(Q(A]B*35M 3N6:0PH \VF^,VCPSR1?
MV9>G8Q7/R<X./6M?9,R]HAG_  NK1_\ H%WW_CG^-'LF'M4=OX<UV+Q'HL.I
MP6\T$4I8*LH&2 <9X[5G)<KL:)W5S5I#.$;XIZ6GB,Z*;"[\T77V;S/EV[MV
MW/7.,UI[-VN9^T5['=UF:!0 V21(8GDD8(B LS'H .IH PO"OBRQ\6V=Q<6:
MO'Y$IC9'QG'9OH152BXDQDI;&_4E"T 5KZ^M]/MC<7+[8QQTR2?05<*<JCY8
MF56K"C'FF]#GFTC3?$ERVH6]U(H) E3;SG^G%=GMJF'7))>AYKPU'&2]K"7J
M;\D\,*_8X9HEN1'B*)G&>!QQUKSY2N]]3VZ=)I)V?*CC_"?_  D;ZS<+J1N1
M;E&$GG9P&[;?_K5QT?:\SYMCW,P^IJC%T;7Z6_4L^'_!<^CZX;Z2\22- PC"
M@@MGCYJJEAW"7,V98S,XXBC[-1LWO_P"GH3^)E\4R&_,XM06,QDXC YQM[>G
M2II^U]I[VQMBU@WA5[*W-I:V_P SJKVVLM?T\Q)<JZ!LB2)@VUA7HT:WLY<T
M=3YG%85U(^SJ)HS;2;2O"[M9R7#O/(0TC;>%],^E=4XU<2N=+0\^G*A@7[-O
M5[G2*P90RD$$9!'>N'8]1.^J%H&?,_BW_DH&J_\ 7\W_ *%75'X4<LOB.B^)
M/C5O$-^-&TQRVGPO@E.?M$GMZ@'IZGGTJ81MJRIROHCO_AUX)7PSIOVN\0'5
M+E?WG_3)?[@_K_\ 6K.<K[&L(\J.WK,L* /"_B[XA_M'7X])A?,%@/GQT,IZ
M_D,#\ZZ*<;*YA4=W8Z+X-^(?/L+C09W_ 'EN?-@SW0GYA^!Y_&IJKJ53>ECU
M*L34* . O?A7X3B2XO;EKN.-0TLC>?PHZGM6BJ2V,W3B>.:=I2^(/%$>G:9&
M\<-Q,1&'.XI'ZD^R\UNW979BE=V1]-V5G#I]C!9VR;(8$$:+Z #%<K=SJ6A/
M2 ^;9O\ DJ3?]A?_ -JUU?9.;[1])5RG2% ' ?%CQ#_97AG^SX7Q<Z@2G!Y$
M8^\?QX'XFM*:N[F=1V5CS;X:>(?["\60QROMM+W$$F>@)/RG\^/Q-:SC=&4'
M9GT17,=(M &7KUE;W]@(KBY6WPP9'8@#-;X><H3O%7.3%TH5:?+)V&Z%HZ:1
M;.HF\UY2&+ 8'MBG7K.J]K6%A,,L/%ZWN<U<^$[F^\6MJ,%_"UN)A(S!\NA&
M/EP/I7E.BY5.9,^LAF$*6$]E*+O:WD_,[6ZN8;.W>XG<)&@R37?&+F^6)\Y.
M<:<7*6R,6V\7:?<7(A998@QP'<#'X\\5U2P=2*N<,,QHSERZHT-9L'U31[JR
MCE\IY4P&[#Z^U<%2//%Q/9PU94*T:C5[&'X.T&70GNTN;J%YY-O[F-\[0,\G
M\ZQH4W3O=G?F6+CB5%PB[+JR;6O#MM=7IO9;Y;9'P'#XY/L<UZ]#$RC'D4;G
MRF*P4)S]HY6.A@6-+>-8B#&J@*0<\=JXI7;=STH)**4=B2D4?,OC!-_CO6$S
MC=>.,^G-=4?A1RR^(<B7O@/QI&;JV26:QEW;6'RR+V8?4=#V/THTE$-82/HO
M2=4M-:TR#4+*3?!,NY3W'J#Z$=*YFK.S.E.ZNB[2&97B/6HO#_A^\U.7!\E/
MD4_Q.>%'YXIQ5W83=E<\$\&1Z=J7BW[9XAO8([9-T\IN' $KGH.>O)S^%=,K
MI61SQLW=D-I?Q^$/'(NM/N4NK6VG.UXVR)(CU&?7:?S%%N:.HK\LM#Z2@GCN
M;>.>%P\4JAT8="",@UR['424 >9?%_Q)]BTN+0K=\37?SS8[1@\#\3^@-:TX
MZW,JDK*Q!\'/#GD6<_B"X3#SYBM\CH@/S'\2,?A3J2Z!3C;4]4K$U"@#YMF_
MY*DW_87_ /:M=7V3F^T?25<IT@3@9/ H ^</&6M#Q7XUD=9TCM!(+>&1SA40
M'&X^V<FNJ*Y8G-)\TB3Q[8:%9WUE+X?OK>>!H5C=87!*N@ W''J,?B#2@WU"
M:2V/9O GB#_A(_"MK=.V;F(>3/\ [Z]_Q&#^-837*S>#NCIJDHYCQ3H][J,T
M$MJOF*BE2FX#!SUYKNPM:%--2/*Q^&J5FI0U-*RTZXA\.BP>;;.8F3>#G83G
M'Y9KEQ$E4E)QZGH8*+P\8*>MCG_!_AC4=$U.>>\>-4:/8$1\[^>O^?6N"A1E
M"5V?0YECJ.)IJ--=?N-KQ1:37>C,L"EFC<.5'4@5ZN%FH5-3Y7'TY5*-H]#@
M8+::ZG6"&-GD8X  KUY245=GSD(2G+EBM3U6%#'!'&QR54 GUP*^?D[NY]?%
M<L4F<1I?A+4;;Q9_:+74;6ZRL_F*^6?.>"/QYKAA0DJG-?0^AKYA1GA?9*.M
MDK=C9\4:/=ZF+=[7#^7D%"V.O>O:PM:%*ZD?&X_#5*UG#H:&AV,VG:3%;3L#
M(,D@'(7)Z5A7J*I4<D=6%I2HTE"6YHUB=)\S^+!_Q<'5!CG[<W'_  *NJ/PG
M++XCV3XB>#5\3Z/Y]J@_M.U4F(_\]%[H?Z>_UK&$N5F\X\R/,_AUXPE\,:Q_
M9][O&GW+[9%(.87Z;L?H?_K5K.-U=&4)<KLSZ KF.@\9^,GB#SK^VT&%OW=N
M!-/[N1\H_ <_C6])=3"H^A#I'P=NM1TBUO9]56UDGC$AA,&XH#T!.X=J'4L[
M J=T9WBWX8W/AC13J:7XO(T<+(HAV% ?XNI[X'XTXU.9V%*GRJYW'PA\0?VC
MX>DTJ9LSZ>0$SWC/3\CD?E45%9W-*;NK'H%S<1V=I-<S'$4*%W(&< #)K(TV
M/EWQ!K4WB#7;O4YR09WRJY^XHX4?@*ZXJRL<DG=W-RR^)GB73K*"SM;BWC@@
M0(BBW7@"I<(LI3:/;_!VIW6L^$M.U"]96N)XRSE5V@G<1T_"L)*SLC>+NKFY
M4E'S;-_R5)A_U%__ &K75]DYOM'TE7*=)QWQ+\0'0O"4RQ/MNKT^1%CL"/F/
MX#^8JX*[(F[(\J\%_#VY\76=Q=_;!9P1.(T8Q;]YQDXY'3C\ZVE/E,8PYCHK
MCX*7,5M*\.M)+*J$I']GQN..!G=Q4^U\BO9>9E?"C7FTCQ2VEW!*PW_[LJ?X
M91]W^H_*G45U<5-V=CWJN<Z#'\2O>1Z0QLMX?<-Y3[P7V_2NG#*#J>^<6.=1
M4?W?](K^$Y;Z2PE-X9"@8>69,Y([]>U7BU!27(9Y?*JZ;]I\KF'J'AS6YO&0
MOXY<6_FJXF\S&Q!U&*\:5*HZO-T/L:.-PT<'[)K6VUMV=58:]IFIW,EO9W:2
MRQ\E0",CU&>OX5TQJ0D[)GD5<)6HQ4JD;)F@%522% )ZD"M+G+9(Y[4=6LM:
MMKW1]-U!1?LA5>H!(Z@'\QQ7/*<9IPB]3TZ.'J8:4*]6'NE7P3H>I:,EV;[$
M:2$;(@X;D9R>*G#TY0OS&V:8JCB''V?3J5_$;ZNNM 0&X$>!Y/E9Q[].^:][
M#*E[/WK>9\5C7B%6]V]NECL(/,^SQ>=CS=HWX]<<UYDK7=MCVX7Y5S;DE(HC
M,$)?>8D+=<E1F@"2@!GDQ%MQB3=G.=HH ?0!&T$3MN:)&;U*@F@"2@!&4,I5
M@"#U!H :D4<>?+C5,]=HQ0 \C(P>E $7V6W_ .>$?_? H /LMO\ \\(_^^!0
M!(JA%"J  .@% "T 1^1#OW^4F[.<[1F@"2@!KQI( '16 _O#- "JBHNU%"J.
MP&* %H 8((@^\1(&SG.T9H DH 2@#B_$.J:K;:V8H))(XUQY:J.'_P >:]3#
MTJ4J=V>%C*]>%;EB[+IYG6@B:V6*XPKRQX9,X/(YQ7F2C>]MCW(3<;-[G.Z%
MX+BT34GO%O&E8*5C!3&W/KZURT\.J<KW/7Q>9RQ--4W&W<S?#6A:]8^)9+F]
M9A!\WF.9-PESTX^O-9TJ=2,[LZL=B\+4PRA3WTMIL:6F^"K72]:_M(73NB$M
M'&1C;GU/?&:TAAU&?-<Y:^:3K4/9-6[LT/$%Y<1:,TVGOD[@&>/G:O<_RKTL
M/"+J6F?-XRI.-'FI%?PG=WUW9S&[9W16'EN_4^HSW[5>+A"$ERF>7U*LX/GU
M['0UQGI!0!E.]Z->2W%V! T9EV>6.@(&,_CUKH2A[+FMKL<C=3VZAS:6OL5+
MG6IX(=241R&2&0K&ZQ911@=36D:$6X^9C/%2BIJVJ>FFA-J5[=QZE#;P22(C
M0ESY<'F'.<=.PJ:4(N#D^_>Q=>K-5%&+Z=%<9K&HSV5U'&MR8D$!<L(=^6!
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M4)QY)+0?;6L%G"L-O$L<:]%6E*3D[R'"$:<>6*LB6I+"@ H * "@ H * "@
>H * "@ H * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g881869g0913171743297.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g881869g0913171743297.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  [ -(# 2(  A$! Q$!_\0
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MN;\+3ZE,UP+PRM&,;3+G.?;-=)652'LY<IM0JJM!32M<**;(2L;,.H!->-^
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MV.AYZ&EN=/-S=PS-,0L3!PH49R/?K@]ZN44^>0.E!BT4E%0:"T4E% "T4E%
'"T4E% '_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
